PubMed Health⌕ Search

PubMed · 10997244

Eruption process of the second molar.

Abstract

The second molar is located at the distal of the first molar, and we must be aware of its stage of development when we plan to move the first molar distally. Few researchers have investigated the development of second molars. The purpose of this study was to observe the eruption process of the maxillary and mandibular second molars by using 238 panoramic radiographs. The developmental stages of the second molar were divided into four stages: the whole crown calcified = stage 1; beginning root formation = stage 2; initial formation of the radicular bifurcation = stage 3; and the root length is equal to the crown height = stage 4. The mesiodistal crown width of the first and second molars, axial inclination and eruption rate of the second molar, and the space available for emergence of the second molar at each stage were measured, and the statistical analysis was made to assess the developmental changes. It was learned that the mandibular second molars began to erupt at stage 3 and the maxillary second molars at stage 2. The axial inclination of the mandibular second molars maintained almost the same angle and the maxillary second molars were uprighted gradually from stage 1 to 4. The available space increased significantly from stage 1 to 2 in both second molars. It is suggested that the space available for emergence of the second molar is prepared before stage 2, and then the tooth begins to erupt. As the maxillary second molars, there was further increase in the available space after stage 3. Negative correlation was seen between the mesiodistal crown width of the mandibular second molar and the available space in stage 2. Positive correlation was seen between the mesiodistal crown width of maxillary second molar and the available space in stage 3. It is suggested that greater increase in the space available for emergence of the second molar could be expected in the maxillary dental arch, if the mesiodistal crown width of the second molar required it.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H H Tsai. Eruption process of the second molar.. https://pubmed.ncbi.nlm.nih.gov/10997244/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Prevalence and risk factors for persistent faecal carriage of extended spectrum beta-lactamase producing Escherichia coli in a paediatric community population.

OBJECTIVE: To investigate clinical and microbiological factors associated with persistent faecal carriage of extended spectrum beta-lactamase (ESBL) producing Escherichia coli in infants. METHODS: Between 2010 and 2022, children aged 3 months to 2 years old were sampled in a community setting in France, at two visits, V1 and V2, 3-24 months apart, to screen for prolonged faecal carriage of ESBL-producing E. coli. Patient clinical information and whole genome sequence of each isolate were used for association studies. RESULTS: A total of 4641 children were sampled. 375 (8%) carried an ESBL-producing Enterobacterales, among which 142 of ESBL-producing E. coli carriers were once again sampled at V2 and included in this study. 21.8% (n = 31/142) and 18.4% (n = 16/99) carried the same ESBL-producing E. coli clone for at least 3 and 6 months, respectively. B2 phylogroup, and among which ST131 clones were associated with an increased risk of persistent carriage. Multivariate analysis identified virulence associated genes involved in adhesion (papC/papGII allele and a tia-like gene) and encoding toxin (senB) as major risk factors for persistence. A genome wide association study highlighted the potential role of the frz metabolic operon, known to be involved in enterocytes adhesion/internalisation. CONCLUSION: Main extraintestinal pathogenic E. coli genomic features (phylogenetic background, adhesion properties) are associated with ESBL-producing E. coli gut colonisation persistence in infants, which could potentially lead to an increased risk of febrile urinary tract infection in these patients.

Child↗

Extensive and differential platinum chemotherapy mutagenesis in livers of children.

Childhood cancer survivors often experience late adverse effects that may be linked to chemotherapy mutagenesis. We studied chemotherapy mutagenesis in normal pediatric tissues using duplex sequencing (NanoSeq) to enable the detection of mutations from single DNA molecules. We found that platinum chemotherapeutics increased the mutation burdens of normal pediatric tissues to levels seen in adults. In the liver, platinum agents imparted a tissue-specific mutational signature that was absent from other tissues. Gene-focused duplex sequencing revealed that chemotherapy mutagenesis generates a great diversity of nonsynonymous variants, some of which may have functional potential, such as leukemogenic variants in blood. Our findings demonstrate extensive chemotherapy mutagenesis in normal tissues of children, which may provide a plausible link between chemotherapy exposure and adverse effects in later life.

Child↗

Clinical and immunological characterization of a child with a homozygous TBK1 kinase-domain truncation.

TBK1 is a serine-tyrosine kinase protein that transmits signals from pattern recognition receptors to the NF-κB pathway leading to production of Type 1 Interferons. Mutations in this protein have been associated with arthritis, vasculitis, herpes simplex encephalitis and amyotrophic lateral sclerosis. In the current study, we characterized the functional consequences of a TBK1-variant bearing a truncation in exon 4 and 5 in a patient with poly arthritis resembling juvenile idiopathic arthritis and necrotizing encephalitis. The truncation was associated with reduced TBK1 protein abundance and altered phosphorylation. The variant was associated with increased basal/and or Poly-I: C induced IL-6, TNFα, IL-1β and IL-18 and type 1 Interferon ex vivo. Our findings expand the phenotypic spectrum of TBK1 loss-of-function variants and may provide insight into the management of immune dysregulation in affected patients.

Child↗